Thomson Scientific Launches Thomson Innovation

The Thomson CorporationThomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, has launched its new intellectual property research and analysis solution, Thomson Innovation. For the first time, researchers will be able to simultaneously search worldwide editorially enhanced patent data, Asian patent data translated into English, scientific literature, and business and news sources.

"The global intellectual property market is changing rapidly, and organizations need to be aware of changes in the evolving landscape, such as the proliferation of patenting activity in Asia," said David Brown, Executive Vice President, Corporate Markets, Thomson Scientific. "It's more critical than ever for our customers to have access to the most authoritative patent data, and to incorporate complementary sources, like scientific literature, in their intellectual property research."

Designed in collaboration with more than 1,800 customers, Thomson Innovation sets a new standard in intellectual property research and analysis that will help companies accelerate ideation, improve productivity, minimize risks and gain a competitive advantage. It provides:

  • Comprehensive prior art searching with the ability to search patents and scientific literature simultaneously
  • Expanded Asian patent coverage, including translations of Japanese full-text and additional editorially enhanced abstracts of Chinese data
  • A fully integrated searchable database combining Derwent World Patent Index® (DWPISM) with full-text patent data to provide the most comprehensive patent records available
  • Support of strategic intellectual property decisions through:
    • powerful analysis and visualization tools, such as charting, citation mapping and search result ranking
    • and, integration of business and news resources
  • Enhanced collaboration capabilities, including customizable folder structures that enable users to organize, annotate, search and share relevant files

Thomson Innovation is being launched in phases, and the first release is available now and includes global, full-text patent sources, including Japan. In rapid succession, it will be followed by the addition of Derwent World Patents Index, scientific literature, business information and news. A series of additional enhancements will be delivered throughout 2008.

For more information about Thomson Innovation, visit www.thomsoninnovation.com.

About The Thomson Corporation
The Thomson Corporation is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation’s common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC). Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development—from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at http://scientific.thomson.com.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...